UGT1A6 genotype-related pharmacokinetics of deferiprone (L1) in healthy volunteers.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  British Journal of Clinical Pharmacology

• Publication date

  2008-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1365-2125.2008.03103.xPMID 18318774PMCID PMC2485226
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Genetic Variants of UGT1A6 Influence Risk of Colorectal Adenoma Recurrence

  2006cited by this paper
• In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises.

  2006cited by this paper
• Effects of Combined UDP-Glucuronosyltransferase (UGT) 1A1*28 and 1A6*2 on Paracetamol Pharmacokinetics in β-Thalassemia/HbE

  2006cited by this paper
• UDP Glucuronosyltransferase (UGT) 1A6 Pharmacogenetics: I. Identification of Polymorphisms in the 5′-Regulatory and Exon 1 Regions, and Association with Human Liver UGT1A6 Gene Expression and Glucuronidation

  2005cited by this paper
• Pharmacogenomics of Deferiprone Metabolism.

  2005cited by this paper
• UDP-glucuronosyltransferase 1A6: structural, functional, and regulatory aspects.

  2005cited by this paper
• Genetic polymorphisms of UGT1A6 in a Japanese population.

  2005cited by this paper
• UDP Glucuronosyltransferase (UGT) 1A6 Pharmacogenetics: II. Functional Impact of the Three Most Common Nonsynonymous UGT1A6 Polymorphisms (S7A, T181A, and R184S)

  2005cited by this paper
• Genetic variants in the UGT1A6 enzyme, aspirin use, and the risk of colorectal adenoma.

  2005cited by this paper
• Human UGT1A6 pharmacogenetics: identification of a novel SNP, characterization of allele frequencies and functional analysis of recombinant allozymes in human liver tissue and in cultured cells.

  2004cited by this paper
• Human udp-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid.

  2004cited by this paper
• Benefits and Risks of Deferiprone in Iron Overload in Thalassaemia and Other Conditions

  2003cited by this paper
• The importance of cysteine 126 in the human liver UDP-glucuronosyltransferase UGT1A6.

  2002cited by this paper
• Deferiprone (L1) as an adjuvant therapy for Plasmodium falciparum malaria.

  2002cited by this paper
• CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk.

  2001cited by this paper
• Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms.

  2001cited by this paper
• Importance of histidine residues for the function of the human liver UDP-glucuronosyltransferase UGT1A6: evidence for the catalytic role of histidine 370.

  2000cited by this paper
• UDP-glucuronosyltransferase (UGT1A1*28 and UGT1A6*2) polymorphisms in Caucasians and Asians: relationships to serum bilirubin concentrations.

  1999cited by this paper
• An investigation into variability in the therapeutic response to deferiprone in patients with thalassemia major.

  1999cited by this paper
• Structural and functional studies of UDP-glucuronosyltransferases.

  1999cited by this paper
• Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients.

  1998cited by this paper
• Genetic polymorphism in the human UGT1A6 (planar phenol) UDP-glucuronosyltransferase: pharmacological implications.

  1997cited by this paper
• The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes.

  1994cited by this paper
• Comparison of the pharmacokinetics of 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in healthy volunteers, with and without co-administration of ferrous sulfate, to thalassemia patients.

  1993cited by this paper
• Subcellular distribution of desferrioxamine and hydroxypyridin‐4‐one chelators in K562 cells affects chelation of intracellular iron pools

  1993cited by this paper
• Urinary metabolic profiles in human and rat of 1,2-dimethyl- and 1,2-diethyl-substituted 3-hydroxypyridin-4-ones.

  1992cited by this paper
• Efficacy and safety of oral iron chelator L1 in anaemic rheumatoid arthritis patients.

  1989cited by this paper
• Plasma ferritin determination as a diagnostic tool.

  1986cited by this paper
• Oxazepam kinetics: effects of age and sex.

  1980cited by this paper
• Recommendations for Measurement of Serum Iron in Human Blood *

  1978cited by this paper

• UGT1A6 variants and deferiprone-induced ADRs: a complication-specific analysis in Iranian thalassemia patients.

  2026cites this paper
• The pharmacokinetic and safety profile of single-dose deferiprone in subjects with sickle cell disease

  2022cites this paper
• Action of iron chelator on intramyocardial hemorrhage and cardiac remodeling following acute myocardial infarction

  2020cites this paper
• Human variability in isoform-specific UDP-glucuronosyltransferases: markers of acute and chronic exposure, polymorphisms and uncertainty factors

  2020cites this paper
• The UDP-Glycosyltransferase (UGT) Superfamily: New Members, New Functions, and Novel Paradigms.

  2019cites this paper
• Electrochemical Determination of Deferiprone Using PVC Membrane Sensors

  2018cites this paper
• Pharmacogenetics: Applications to Pediatric Patients.

  2018cites this paper
• Population pharmacokinetics and dosing recommendations for the use of deferiprone in children younger than 6 years

  2017cites this paper
• Pyrophosphate functionalized silver nanoparticles for colorimetric determination of deferiprone via competitive binding to Fe(III)

  2017cites this paper
• Drug-Based Lead Discovery: The Novel Ablative Antiretroviral Profile of Deferiprone in HIV-1-Infected Cells and in HIV-Infected Treatment-Naive Subjects of a Double-Blind, Placebo-Controlled, Randomized Exploratory Trial

  2016influential citation
• Genetic polymorphisms of human UDP-glucuronosyltransferase (UGT) genes and cancer risk

  2016cites this paper
• Safety profile of a liquid formulation of deferiprone in young children with transfusion-induced iron overload: a 1-year experience

  2016cites this paper
• Sampling Optimization in Pharmacokinetic Bridging Studies: Example of the Use of Deferiprone in Children With β‐Thalassemia

  2016cites this paper
• Safety profile of a liquid formulation of deferiprone in young children with transfusion-induced iron overload: a 1-year experience.

  2016cites this paper
• Effects of UGT1A9 genetic polymorphisms on monohydroxylated derivative of oxcarbazepine concentrations and oxcarbazepine monotherapeutic efficacy in Chinese patients with epilepsy

  2016cites this paper
• Population pharmacokinetics and dosing recommendations for the use of deferiprone in children younger than 6 years of age

  2016cites this paper
• The Implication of the Polymorphisms of COX-1, UGT1A6, and CYP2C9 among Cardiovascular Disease (CVD) Patients Treated with Aspirin.

  2015cites this paper
• Model-based dosing recommendations for the use of deferiprone in children affected by transfusional iron overload younger than 6 years of age

  2015cites this paper
• Population pharmacokinetics of deferiprone in healthy subjects.

  2014cites this paper
• Transcriptional regulation of human UDP-glucuronosyltransferase genes

  2014cites this paper
• Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review.

  2014cites this paper
• Combined versus monotherapy or concurrent therapy for treatment of thalassaemia.

  2014influential citation
• Three most common nonsynonymous UGT1A6*2 polymorphisms (Thr181Ala, Arg184Ser and Ser7Ala) and therapeutic response to deferiprone in β-thalassemia major patients.

  2013cites this paper
• Deferiprone (GPO‐L‐ONE®) monotherapy reduces iron overload in transfusion‐dependent thalassemias: 1‐year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO‐L‐ONE; A001) from Thailand

  2013cites this paper
• Comparison of Pharmacokinetics and Urinary Iron Excretion of Two Single Doses of Deferiprone in β-Thalassemia/Hemoglobin E Patients

  2012cites this paper
• Quantitative determination of deferiprone in human plasma by reverse phase high performance liquid chromatography and its application to pharmacokinetic study.

  2012cites this paper
• Development of a fast LC-MS/MS assay for the determination of deferiprone in human plasma and application to pharmacokinetics.

  2012cites this paper
• Integration of Pharmacogenetics and Pharmacogenomics in Drug Development: Implications for Regulatory and Medical Decision Making in Pediatric Diseases

  2012cites this paper
• Inhibitory Effects of Commonly Used Herbal Extracts on UGT 1 A 4 , 1 A 6 , and 1 A 9 Enzyme Activities

  2011cites this paper
• Pharmacokinetics of Deferiprone in Patients with β-Thalassaemia

  2011cites this paper
• Pharmacokinetics of Deferiprone in Patients with β-Thalassaemia : Impact of Splenectomy and Iron Status.

  2011cites this paper
• Inhibitory Effects of Commonly Used Herbal Extracts on UDP-Glucuronosyltransferase 1A4, 1A6, and 1A9 Enzyme Activities

  2011cites this paper
• Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system

  2010cites this paper
• Genetic polymorphism in metabolism and host defense enzymes: Implications for human health risk assessment

  2010cites this paper
• Deferiprone Glucuronidation by Human Tissues and Recombinant UDP Glucuronosyltransferase 1A6: An in Vitro Investigation of Genetic and Splice Variants

  2009cites this paper
• Pharmaco/ferrokinetic-related pro-oxidant activity of deferiprone in β-thalassemia

  2009cites this paper
• Bioequivalence study of a film-coated tablet of deferiprone in healthy Thai volunteers.

  2009cites this paper
• Deferiprone targets aconitase: Implication for Friedreich's ataxia treatment

  2008cites this paper